Wallingford, CT, United States of America

Valentin K Gribkoff

This inventor holds 17 USPTO granted patents and 10 published patent applications. Top assignees: Bristol-Myers Squibb Compnay, Knopp Neurosciences, Inc., Bristol-Myers Squibb. Active years: 1996-2017.

USPTO Granted Patents = 17 (Patent Applications = 10)

% Patents Active = 94.1

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 223(Granted Patents)

Company Filing History:

10 out of 3,736

Bristol-Myers Squibb Compnay

patents

4 out of 5

Knopp Neurosciences, Inc.

Knopp Biosciences, LLC

patents

5. 1 out of 834,411

Other

patents

Years Active: 1996-2017

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9849116 - Compositions and methods of using (R)-pramipexole (2017-12-26),

2. 8524695 - Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same (2013-09-03),

3. 8518926 - Compositions and methods of using (R)-pramipexole (2013-08-27),

4. 8445474 - Compositions of R(+) and S(−) pramipexole and methods of using the same (2013-05-21),

5. 8017598 - Compositions of R(+) and S(−) pramipexole and methods of using the same (2011-09-13),

6. 7041496 - DNA encoding rodent KCNQ2 potassium channel (2006-05-09),

7. 6939968 - Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives (2005-09-06),

8. 6893858 - Human kcnq5 potassium channel, methods and compositions thereof (2005-05-17),

9. 6855829 - 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease (2005-02-15),

10. 6469042 - Fluoro oxindole derivatives as modulators if KCNQ potassium channels (2002-10-22),

11. 6326526 - Melatonin receptor-deficient mice and uses thereof (2001-12-04),

12. 6271249 - Diphenyl imidazoles as potassium channel modulators (2001-08-07),

13. 6077861 - Diphenyl triazoles as potassium channel modulators (2000-06-20),

14. 5869509 - Diphenyl oxadiazolones as potassium channel modulators (1999-02-09),

15. 5621007 - Method for regulation of transmembrane chloride conductance (1997-04-15),

Title: The Innovative Contributions of Valentin K Gribkoff

Introduction

Valentin K Gribkoff is a notable inventor based in Wallingford, CT, with a remarkable portfolio of 17 patents. His work primarily focuses on pharmaceutical compositions and methods that address various neurodegenerative diseases and related conditions.

Latest Patents

Gribkoff's latest patents include compositions and methods of using (R)-pramipexole, which involve pharmaceutical compositions that combine (R)-pramipexole with secondary therapeutic agents. These agents may include dopamine agonists, COMT inhibitors, and neurotrophic factors, among others. Another significant patent involves modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine, aimed at treating neurodegenerative diseases through controlled release mechanisms.

Career Highlights

Throughout his career, Gribkoff has made significant contributions while working with prominent companies such as Bristol-Myers Squibb Company and Knopp Neurosciences, Inc. His expertise in pharmaceutical development has led to advancements in treatments for conditions related to mitochondrial dysfunction and oxidative stress.

Collaborations

Gribkoff has collaborated with esteemed colleagues, including Piyasena Hewawasam and Nicholas A Meanwell, to further enhance the impact of his research and innovations in the pharmaceutical field.

Conclusion

Valentin K Gribkoff's innovative work in the pharmaceutical industry has led to significant advancements in the treatment of neurodegenerative diseases. His contributions continue to influence the development of effective therapeutic solutions.